Science
We are excited to announce our new partnership with Scendea, a leading regulatory and product development consulting group.
By combining ERBC’s preclinical expertise with Scendea’s regulatory and clinical strategy, we offer a seamless and optimized pathway for drug development.
This collaboration empowers you to:
✅ Enhance the translational value of preclinical data
✅ De-risk drug development programs by integrating regulatory and safety strategies early
✅ Accelerate market access with comprehensive, end-to-end scientific and regulatory support
One of the key challenges in drug development is predicting and mitigating drug-induced cardiotoxicity—a leading cause of late-stage failures. Our latest white paper, developed jointly by ERBC and Scendea, explores:
The importance of lead optimization in reducing safety risks
Functional cardiotoxicity mechanisms and their impact on drug candidates
Regulatory guidelines for cardiovascular safety evaluation
Strategies for early detection and risk mitigation in preclinical phases
DOWNLOAD THE WHITE PAPER NOW and gain strategic insights into minimizing cardiotoxic risks while optimizing lead candidates.
We look forward to supporting your development programs with science-driven, regulatory-compliant solutions. Feel free to reach out if you’d like to discuss how ERBC and Scendea can assist your projects.
